Developer docs
API playgroundTry for free, no card

Search company profiles

Skin Analytics

Full company profile

uuid00007zp

Namestring
Skin Analytics
Legal namestring
Skin Analytics Limited
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Skin Analytics is a UK-based medical device company that develops and commercializes AI-powered dermatology software for autonomous skin cancer assessment. Founded in 2012, the company's flagship product is DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE-marked and UKCA Class IIa-certified AI as a Medical Device that uses custom deep learning ensembles to analyze images of skin lesions and triage patients into the appropriate care pathway. DERM identifies melanoma, squamous cell carcinoma, basal cell carcinoma, Bowen's disease, actinic keratosis, and atypical nevi with validated sensitivity thresholds of 95%+ for melanoma and SCC, and is deployed across more than 25 NHS partner sites in the UK, with over 230,000 patients assessed and 20,000+ cancers detected over six years of clinical use. In 2026 the company launched DERM Zero, a smartphone-compatible version of the same Class III regulated AI, extending deployment beyond hospitals to primary care, pharmacies, and community settings.

The company's business model centers on annual subscription fees (Annual Product Fees) paid by NHS trusts and healthcare providers for access to the DERM platform, supplemented by per-case fees of £20 for clinician reviews and custom software development at £850 per person day. Secondary revenue streams include Bupa-branded remote skin assessment services (where Skin Analytics invoices the insurer directly) and direct-to-consumer Mole Check and General Dermatology services in the UK. European expansion is being executed via channel partnerships with Affidea (pan-European, starting Romania and Lithuania) and Human Bytes (Nordic), with a stated objective of US market entry supported by the £15M Series B funding round closed in April 2025 led by Intrepid Growth Partners.

Skin Analytics is headquartered in London with a registered office in Cambridge, operates with 51-100 employees, and is led by founder and CEO Neil Daly alongside a clinical and AI leadership team including Dr Jack Greenhalgh (AI Director) and Dr Dilraj Kalsi (Clinical AI Lead). The company has accumulated an unusually deep stack of certifications and endorsements for a company of its size, including ISO 13485:2016, ISO 27001, NHS DSP Toolkit, Cyber Essentials, DCB 0129, DTAC, CQC registration, the NHSX Award (2021), CogX Best Innovation in Computer Vision (2019), G-Cloud 14 Framework placement (2024), and a NICE Early Value Assessment recommendation (2025) for use within NHS Trusts.

Short descriptiontext

Skin Analytics is a UK-based medical device company that develops DERM, a Class III CE-marked AI platform using deep learning ensembles to autonomously screen skin lesions for cancer. The company sells annual subscriptions and per-case fees to NHS trusts, private insurers like Bupa, and European channel partners, and has assessed 230,000+ patients across 25+ NHS sites.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
dermatology AI, skin cancer detection, medical imaging AI, teledermatology platform, AI medical device
Industry2 codes
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLALAGAA
Dermatology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
NAICS code1 code
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Health Services8000
Product category
AI Dermatology Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1NHS and Healthcare Provider Contracts
TypeSubscription Recurring
Description

Annual Product Fee paid by NHS trusts and healthcare providers for access to DERM platform and services, with additional per-case fees for clinician reviews (£20 per case). Custom software development available at £850 per person day.

skin-analytics.com
2Private Healthcare / Insurance
TypeSubscription Recurring
Description

Bupa customers receive remote skin assessment services with Skin Analytics invoicing Bupa directly for assessments. Patients may receive invoices for any contribution towards costs not covered by their insurance policy.

skin-analytics.com
3European Licensing
TypeLicensing Royalties
Description

Working with European partners to make DERM Zero available from June 2026, enabling clinical-grade skin cancer checks across EU primary care, pharmacies, and community settings.

skin-analytics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details2 tiers
1Annual Product Fee for NHS and healthcare provider access to DERM platform
ModelSubscriptionBilling cadenceAnnual
Notes

Annual Product Fee for platform access; additional £20 per case for clinician review; custom software development at £850 per person day +VAT; additional in-person training at £850 per day +VAT (EU: £1,200 per day)

skin-analytics.com
2Bupa private customer remote skin assessment service
ModelSubscriptionBilling cadencePer case
Notes

Skin Analytics invoices Bupa directly; Bupa customers may receive invoices for any contribution not covered by their insurance policy

skin-analytics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1DERM
Description

Deep Ensemble for the Recognition of Malignancy - Class III CE marked AI as a Medical Device for autonomous skin cancer detection. Powers both clinical pathway deployment and DERM Zero smartphone application.

skin-analytics.com
+1 more record
Core offering1 text field

Skin Analytics develops and sells DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE marked AI as a Medical Device that autonomously analyzes images of skin lesions to triage patients and detect melanoma, squamous cell carcinoma, basal cell carcinoma, and other skin cancers. The platform combines proprietary deep learning ensembles with a custom teledermatology system to integrate into NHS dermatology pathways. DERM Zero extends this Class III regulated AI to standard smartphones, enabling clinical-grade skin cancer assessment in primary care, pharmacies, and community settings without specialist equipment or hospital appointments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 99.5% accuracy in ruling out melanoma and skin cancer
+5 more records
Product overview1 text field

Skin Analytics offers a portfolio of AI-powered dermatology products centered on its Class III CE-marked DERM (Deep Ensemble for the Recognition of Malignancy) platform. DERM provides autonomous skin cancer detection using deep learning algorithms to analyze skin lesion images with 95%+ sensitivity for melanoma and squamous cell carcinoma. The product suite includes DERM (hospital/clinic-based with dermoscopic hardware), DERM Zero (smartphone-based autonomous assessment), and NHS pathway integrations combining AI triage with teledermatology review. Additional services include mole/lesion assessment for patients and general dermatology consultation services, with Bupa offering a branded remote skin assessment powered by Skin Analytics technology.

Product and service5 records
1DERM (Deep Ensemble for the Recognition of Malignancy)
CategoryAI Medical Device (Core Platform)
Description

Class III CE-marked and UKCA Class IIa certified AI as a Medical Device (AIaMD) for autonomous skin cancer detection. DERM uses deep ensemble methods combining multiple neural network models to analyze dermoscopic images of skin lesions and triage patients for melanoma, squamous cell carcinoma, basal cell carcinoma, Bowen's disease, actinic keratosis, and atypical nevi with minimum sensitivity thresholds of 95% for melanoma and SCC. Built around a custom teledermatology platform for end-to-end skin cancer pathway management in NHS secondary and primary care.

2DERM Zero
CategoryAI Medical Device (Smartphone Variant)
Description

World's first Class III CE-marked medical device technology approved to autonomously assess skin cancer from a standard smartphone. DERM Zero enables clinical-grade skin cancer checks in primary care, pharmacies, or community settings without requiring a dermoscope or hospital appointment, processing images captured from standard smartphone cameras for autonomous skin cancer assessment using the same Class III regulated AI as DERM.

3Mole and Lesion Assessment Service
CategoryDirect-to-Consumer Dermatology Service
Description

Patient-facing direct-to-consumer service for assessing skin lesions using DERM technology, offering faster assessment and results within 24 hours compared to traditional face-to-face dermatology appointments. Available directly to UK patients through the Skin Analytics services website.

4General Dermatology Service
CategoryDirect-to-Consumer Dermatology Service
Description

Non-urgent general dermatology assessment service for skin concerns using the Skin Analytics platform with dermatologist review of uploaded images. Available directly to UK patients through the company's services website as a consumer offering.

5Bupa Remote Skin Assessment
CategoryInsurance Channel Dermatology Service
Description

Partnership service with Bupa providing Bupa customers with access to a remote skin assessment using Skin Analytics technology. Customers receive a kit with a smartphone and dermoscopic lens, upload photos of moles via app alongside their medical history, and receive dermatologist assessment within 24 hours. Skin Analytics invoices Bupa directly for the assessment service.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
1Human Bytes
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-11-04
Description

Strategic partnership to bring DERM, the world's only autonomous AI for assessment and triage of suspected skin cancer, to the Nordic countries.

skin-analytics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-18
Description

Pan-European provider of community-based polyclinics and advanced diagnostics has partnered with Skin Analytics to implement AI-based skin cancer detection across several European countries, starting with Romania and Lithuania. Aims to improve early diagnosis and patient access to skin cancer care with plans to expand further in Europe.

3Bupa
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Bupa has engaged Skin Analytics to provide its customers with access to a new remote skin assessment service. Customers receive a kit with smartphone and dermoscopic lens, upload photos via app, and receive dermatologist assessment within 24 hours. Skin Analytics invoices Bupa directly for this service.

skin-analytics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

NHS accelerator program that supported Skin Analytics since 2016 as part of their journey to bring AI skin cancer detection technology to the NHS.

5NHS National Innovation Accelerator
Strategic tierMinorTypeStrategic or Co-development Partner
Description

NHS program supporting Skin Analytics since 2016 to accelerate adoption of innovative AI technology in the NHS.

skin-analytics.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Healthdirect Australia is testing an integration with ChatGPT to create a health assistant, collaborating with Infermedica, Skin Analytics, AWS, and DEPT on the project.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

25+ NHS partners using DERM across NHS sites including Chelsea and Westminster Hospital, Ashford & St. Peter's Hospitals, West Suffolk NHS Foundation Trust, Manchester University NHS Foundation Trust, and others. Jersey GP Surgery became first in Channel Islands to use DERM.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Teledermatology platform connecting users to dermatologists for asynchronous skin lesion assessment. Comparable as a remote skin assessment service provider, though relies on human clinician review rather than autonomous AI.

TypeDirect peer
Description

US-based leader in dermatology imaging systems (VECTRA, IntelliStudio, DermaGraphix) with AI features for skin lesion analysis. Comparable provider of imaging and AI tools used by dermatology clinics and research institutions.

TypeDirect peer
Description

Amsterdam-based AI dermatology company offering a CE-marked smartphone app for skin cancer risk assessment. Direct competitor in autonomous dermatology AI targeting both consumer and B2B channels across Europe and Australia.

TypeBroad incumbent
Description

Global medical imaging incumbent offering a portfolio of AI-assisted radiology and imaging applications, including dermatology-adjacent imaging AI. Comparable as a broad incumbent that could bundle AI dermatology tools into enterprise imaging contracts.

TypeEmerging player
Description

US company offering AI-driven non-invasive cardiac diagnostic analysis with multiple regulatory clearances and established reimbursement. Comparable as a regulated AI medical device company with deep clinical evidence, NHS-relevant footprint, and similar enterprise sales motion.

TypeEmerging player
Description

US clinical decision support platform used by dermatologists and primary care for image-based differential diagnosis. Comparable as an AI/imaging dermatology decision support tool used in clinical workflows, though primarily clinician-facing reference rather than autonomous triage.

TypeDirect peer
Description

US-based developer of an FDA-cleared handheld AI device for primary care skin cancer detection. Direct competitor in autonomous dermatology AI with FDA clearance, pursuing the same primary-care workflow Skin Analytics targets with DERM Zero.

TypeDirect peer
Description

German manufacturer of dermoscopy hardware and AI-based skin imaging software used by dermatologists worldwide. Comparable as a provider of AI-assisted dermatology imaging used in clinical workflows and mole monitoring.

TypeDirect peer
Description

Canadian company offering DermEngine (teledermatology/AI imaging platform) and MoleScope (smartphone dermoscopy attachment). Comparable as a combined AI imaging plus smartphone dermoscopy workflow targeting dermatologists and primary care.

10IDx / Digital Diagnostics
TypeDirect peer
Description

Pioneer of fully autonomous AI diagnostics (IDx-DR, the first FDA-authorised autonomous AI diagnostic). Comparable as a regulated autonomous AI medical device company targeting primary care workflow, providing a regulatory and commercial precedent for Skin Analytics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Skin Analytics

AI Dermatology Medical Devicesskin-analytics.com

Skin Analytics is a UK-based medical device company that develops DERM, a Class III CE-marked AI platform using deep learning ensembles to autonomously screen skin lesions for cancer. The company sells annual subscriptions and per-case fees to NHS trusts, private insurers like Bupa, and European channel partners, and has assessed 230,000+ patients across 25+ NHS sites.

What Skin Analytics does

Skin Analytics is a UK-based medical device company that develops and commercializes AI-powered dermatology software for autonomous skin cancer assessment. Founded in 2012, the company's flagship product is DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE-marked and UKCA Class IIa-certified AI as a Medical Device that uses custom deep learning ensembles to analyze images of skin lesions and triage patients into the appropriate care pathway. DERM identifies melanoma, squamous cell carcinoma, basal cell carcinoma, Bowen's disease, actinic keratosis, and atypical nevi with validated sensitivity thresholds of 95%+ for melanoma and SCC, and is deployed across more than 25 NHS partner sites in the UK, with over 230,000 patients assessed and 20,000+ cancers detected over six years of clinical use. In 2026 the company launched DERM Zero, a smartphone-compatible version of the same Class III regulated AI, extending deployment beyond hospitals to primary care, pharmacies, and community settings.

The company's business model centers on annual subscription fees (Annual Product Fees) paid by NHS trusts and healthcare providers for access to the DERM platform, supplemented by per-case fees of £20 for clinician reviews and custom software development at £850 per person day. Secondary revenue streams include Bupa-branded remote skin assessment services (where Skin Analytics invoices the insurer directly) and direct-to-consumer Mole Check and General Dermatology services in the UK. European expansion is being executed via channel partnerships with Affidea (pan-European, starting Romania and Lithuania) and Human Bytes (Nordic), with a stated objective of US market entry supported by the £15M Series B funding round closed in April 2025 led by Intrepid Growth Partners.

Skin Analytics is headquartered in London with a registered office in Cambridge, operates with 51-100 employees, and is led by founder and CEO Neil Daly alongside a clinical and AI leadership team including Dr Jack Greenhalgh (AI Director) and Dr Dilraj Kalsi (Clinical AI Lead). The company has accumulated an unusually deep stack of certifications and endorsements for a company of its size, including ISO 13485:2016, ISO 27001, NHS DSP Toolkit, Cyber Essentials, DCB 0129, DTAC, CQC registration, the NHSX Award (2021), CogX Best Innovation in Computer Vision (2019), G-Cloud 14 Framework placement (2024), and a NICE Early Value Assessment recommendation (2025) for use within NHS Trusts.

Skin Analytics firmographics

Firmographics
Name
Skin Analytics
Legal name
Skin Analytics Limited
Website
https://skin-analytics.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
101–250 employees
Short description
Skin Analytics is a UK-based medical device company that develops DERM, a Class III CE-marked AI platform using deep learning ensembles to autonomously screen skin lesions for cancer. The company sells annual subscriptions and per-case fees to NHS trusts, private insurers like Bupa, and European channel partners, and has assessed 230,000+ patients across 25+ NHS sites.
Ownership category
akta.pro rank

Skin Analytics industry classification

Industry
Product category
AI Dermatology Medical Devices
NAICS
Medical and Diagnostic Laboratories (62151)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Health Services (8000)
akta.pro industry
PRIMARYHDAAAEAH
Medical Imaging AI
SECONDARYHLALAGAA
Dermatology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)

Keywords

  • Dermatology AI
  • Skin cancer detection
  • Medical imaging AI
  • Teledermatology platform
  • AI medical device

Where Skin Analytics is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Skin Analytics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. NHS and Healthcare Provider Contracts: Annual Product Fee paid by NHS trusts and healthcare providers for access to DERM platform and services, with additional per-case fees for clinician reviews (£20 per case). Custom software development available at £850 per person day.
  2. Private Healthcare / Insurance: Bupa customers receive remote skin assessment services with Skin Analytics invoicing Bupa directly for assessments. Patients may receive invoices for any contribution towards costs not covered by their insurance policy.
  3. European Licensing: Working with European partners to make DERM Zero available from June 2026, enabling clinical-grade skin cancer checks across EU primary care, pharmacies, and community settings.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualAnnual Product Fee for NHS and healthcare provider access to DERM platform
SubscriptionPer caseBupa private customer remote skin assessment service

Go-to-market motion3 records

Distribution channels6 records

Marketing channels6 records

Skin Analytics product offering

Product offering

Core offering

Skin Analytics develops and sells DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE marked AI as a Medical Device that autonomously analyzes images of skin lesions to triage patients and detect melanoma, squamous cell carcinoma, basal cell carcinoma, and other skin cancers. The platform combines proprietary deep learning ensembles with a custom teledermatology system to integrate into NHS dermatology pathways. DERM Zero extends this Class III regulated AI to standard smartphones, enabling clinical-grade skin cancer assessment in primary care, pharmacies, and community settings without specialist equipment or hospital appointments.

Product overview

Skin Analytics offers a portfolio of AI-powered dermatology products centered on its Class III CE-marked DERM (Deep Ensemble for the Recognition of Malignancy) platform. DERM provides autonomous skin cancer detection using deep learning algorithms to analyze skin lesion images with 95%+ sensitivity for melanoma and squamous cell carcinoma. The product suite includes DERM (hospital/clinic-based with dermoscopic hardware), DERM Zero (smartphone-based autonomous assessment), and NHS pathway integrations combining AI triage with teledermatology review. Additional services include mole/lesion assessment for patients and general dermatology consultation services, with Bupa offering a branded remote skin assessment powered by Skin Analytics technology.

Differentiator

Problem solved

Functional benefit

Brands

  • DERM: Deep Ensemble for the Recognition of Malignancy - Class III CE marked AI as a Medical Device for autonomous skin cancer detection. Powers both clinical pathway deployment and DERM Zero smartphone application.
  • DERM Zero

Products and services

  • DERM (Deep Ensemble for the Recognition of Malignancy) Class III CE-marked and UKCA Class IIa certified AI as a Medical Device (AIaMD) for autonomous skin cancer detection. DERM uses deep ensemble methods combining multiple neural network models to analyze dermoscopic images of skin lesions and triage patients for melanoma, squamous cell carcinoma, basal cell carcinoma, Bowen's disease, actinic keratosis, and atypical nevi with minimum sensitivity thresholds of 95% for melanoma and SCC. Built around a custom teledermatology platform for end-to-end skin cancer pathway management in NHS secondary and primary care.
  • DERM Zero World's first Class III CE-marked medical device technology approved to autonomously assess skin cancer from a standard smartphone. DERM Zero enables clinical-grade skin cancer checks in primary care, pharmacies, or community settings without requiring a dermoscope or hospital appointment, processing images captured from standard smartphone cameras for autonomous skin cancer assessment using the same Class III regulated AI as DERM.
  • Mole and Lesion Assessment Service Patient-facing direct-to-consumer service for assessing skin lesions using DERM technology, offering faster assessment and results within 24 hours compared to traditional face-to-face dermatology appointments. Available directly to UK patients through the Skin Analytics services website.
  • General Dermatology Service Non-urgent general dermatology assessment service for skin concerns using the Skin Analytics platform with dermatologist review of uploaded images. Available directly to UK patients through the company's services website as a consumer offering.
  • Bupa Remote Skin Assessment Partnership service with Bupa providing Bupa customers with access to a remote skin assessment using Skin Analytics technology. Customers receive a kit with a smartphone and dermoscopic lens, upload photos of moles via app alongside their medical history, and receive dermatologist assessment within 24 hours. Skin Analytics invoices Bupa directly for the assessment service.

Quantifiable outcome

  • 99.5% accuracy in ruling out melanoma and skin cancer
  • +5 more outcomes

Companies that use Skin Analytics

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Skin Analytics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Skin Analytics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Human BytescoreChannel Partner/ Reseller/ Distributor · 4 November 2025Strategic partnership to bring DERM, the world's only autonomous AI for assessment and triage of suspected skin cancer, to the Nordic countries.
  • AffideacoreStrategic or Co-development Partner · 18 August 2025Pan-European provider of community-based polyclinics and advanced diagnostics has partnered with Skin Analytics to implement AI-based skin cancer detection across several European countries, starting with Romania and Lithuania. Aims to improve early diagnosis and patient access to skin cancer care with plans to expand further in Europe.
  • BupacoreChannel Partner/ Reseller/ DistributorBupa has engaged Skin Analytics to provide its customers with access to a new remote skin assessment service. Customers receive a kit with smartphone and dermoscopic lens, upload photos via app, and receive dermatologist assessment within 24 hours. Skin Analytics invoices Bupa directly for this service.
  • DigitalHealth.LondonminorStrategic or Co-development PartnerNHS accelerator program that supported Skin Analytics since 2016 as part of their journey to bring AI skin cancer detection technology to the NHS.
  • NHS National Innovation AcceleratorminorStrategic or Co-development PartnerNHS program supporting Skin Analytics since 2016 to accelerate adoption of innovative AI technology in the NHS.
  • Healthdirect AustraliaminorStrategic or Co-development PartnerHealthdirect Australia is testing an integration with ChatGPT to create a health assistant, collaborating with Infermedica, Skin Analytics, AWS, and DEPT on the project.
  • NHS Trusts (Various)coreChannel Partner/ Reseller/ Distributor25+ NHS partners using DERM across NHS sites including Chelsea and Westminster Hospital, Ashford & St. Peter's Hospitals, West Suffolk NHS Foundation Trust, Manchester University NHS Foundation Trust, and others. Jersey GP Surgery became first in Channel Islands to use DERM.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Skin Analytics competitors and assessment

Company assessment

Emerging players

  • First Derm: Teledermatology platform connecting users to dermatologists for asynchronous skin lesion assessment. Comparable as a remote skin assessment service provider, though relies on human clinician review rather than autonomous AI.
  • HeartFlow: US company offering AI-driven non-invasive cardiac diagnostic analysis with multiple regulatory clearances and established reimbursement. Comparable as a regulated AI medical device company with deep clinical evidence, NHS-relevant footprint, and similar enterprise sales motion.
  • VisualDx: US clinical decision support platform used by dermatologists and primary care for image-based differential diagnosis. Comparable as an AI/imaging dermatology decision support tool used in clinical workflows, though primarily clinician-facing reference rather than autonomous triage.

Direct peers

  • Canfield Scientific: US-based leader in dermatology imaging systems (VECTRA, IntelliStudio, DermaGraphix) with AI features for skin lesion analysis. Comparable provider of imaging and AI tools used by dermatology clinics and research institutions.
  • SkinVision: Amsterdam-based AI dermatology company offering a CE-marked smartphone app for skin cancer risk assessment. Direct competitor in autonomous dermatology AI targeting both consumer and B2B channels across Europe and Australia.
  • DermaSensor: US-based developer of an FDA-cleared handheld AI device for primary care skin cancer detection. Direct competitor in autonomous dermatology AI with FDA clearance, pursuing the same primary-care workflow Skin Analytics targets with DERM Zero.
  • FotoFinder Systems: German manufacturer of dermoscopy hardware and AI-based skin imaging software used by dermatologists worldwide. Comparable as a provider of AI-assisted dermatology imaging used in clinical workflows and mole monitoring.
  • MetaOptima (MoleScope / DermEngine): Canadian company offering DermEngine (teledermatology/AI imaging platform) and MoleScope (smartphone dermoscopy attachment). Comparable as a combined AI imaging plus smartphone dermoscopy workflow targeting dermatologists and primary care.
  • IDx / Digital Diagnostics: Pioneer of fully autonomous AI diagnostics (IDx-DR, the first FDA-authorised autonomous AI diagnostic). Comparable as a regulated autonomous AI medical device company targeting primary care workflow, providing a regulatory and commercial precedent for Skin Analytics.

Broad incumbents

  • Siemens Healthineers (AI-Rad Companion): Global medical imaging incumbent offering a portfolio of AI-assisted radiology and imaging applications, including dermatology-adjacent imaging AI. Comparable as a broad incumbent that could bundle AI dermatology tools into enterprise imaging contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Skin Analytics social profiles

Digital presence

Skin Analytics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Skin Analytics leadership team

Management profile

Number of profiles

Profiles7 records

Skin Analytics funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Skin Analytics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Skin Analytics

What does Skin Analytics do?

Skin Analytics develops and sells DERM (Deep Ensemble for the Recognition of Malignancy), a Class III CE marked AI as a Medical Device that autonomously analyzes images of skin lesions to triage patients and detect melanoma, squamous cell carcinoma, basal cell carcinoma, and other skin cancers. The platform combines proprietary deep learning ensembles with a custom teledermatology system to integrate into NHS dermatology pathways. DERM Zero extends this Class III regulated AI to standard smartphones, enabling clinical-grade skin cancer assessment in primary care, pharmacies, and community settings without specialist equipment or hospital appointments.

Is Skin Analytics a public or private company?

Skin Analytics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Skin Analytics founded?

Skin Analytics was founded in 2012. It employs 101 to 250 people.

Where is Skin Analytics based?

Skin Analytics is headquartered in London, United Kingdom, in the Europe region.

How does Skin Analytics make money?

Three revenue lines are on record. NHS and Healthcare Provider Contracts are the primary driver. The others are private Healthcare / Insurance and european Licensing.

Who are Skin Analytics's main competitors?

Emerging players on record are First Derm, HeartFlow and VisualDx. Direct peers are Canfield Scientific, SkinVision, DermaSensor, FotoFinder Systems, MetaOptima (MoleScope / DermEngine) and IDx / Digital Diagnostics. Siemens Healthineers (AI-Rad Companion) is listed as a broad incumbent.

Does Skin Analytics have an API?

No public API is recorded for Skin Analytics.

What industry is Skin Analytics in?

Skin Analytics's product category is AI Dermatology Medical Devices. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLALAGAA, Dermatology Telemedicine Platforms. Its NAICS code is 62151 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TelecomreviewafricaAutonomous Skin Cancer Detection Arrives on SmartphonesSkin Analytics has launched DERM Zero, a CE-marked AI medical device that autonomously assesses skin cancer using a smartphone. The device, building on clinical deployment in the UK, can deliver rapid, clinical-grade skin cancer assessments and is approved in Europe.TechRoundHow Are UK HealthTech Companies Pushing For More Reliable Solutions In The Industry?UK HealthTech companies are shifting focus from innovation to reliability amid rising cyber threats targeting the healthcare sector, with SonicWall reporting 264,000 intrusion prevention events in UK healthcare between January and May 2026, compared to 27,000 for all of 2025. Industry experts from multiple UK healthtech companies and organizations emphasize that reliability requires evidence-based product development, rigorous regulatory compliance, high data quality standards, and collaboration between developers, clinicians, and regulators. The article includes perspectives from executives at companies including ZoomDoc, Freshworks, Skin Analytics, and others discussing how the sector can build more trustworthy and accountable digital health solutions.LaingBuisson NewsSkin Analytics launches smartphone-based version of AI skin cancer technologySkin Analytics launched a smartphone-based AI skin cancer assessment platform, DERM Zero, which is certified as a Class III medical device under EU regulations. The platform uses images taken on standard smartphones to identify suspicious skin lesions that need further clinical investigation and aims to expand access to skin cancer assessments outside hospital settings.EIN PresswireHealthdirect Australia, Infermedica and Partners Collaborate on ChatGPT Health Service PilotHealthdirect Australia announced a collaboration with Infermedica, Skin Analytics, AWS, and DEPT to bring Healthdirect into ChatGPT, using Infermedica's triage technology and Skin Analytics' autonomous skin cancer screening. The pilot will start with an invited group of consumers, with safeguards and governance before wider release.Med-Tech InsightsDigital medical device for cancer detection certified for smartphone useSkin Analytics certified DERM Zero, an AI skin cancer detection tool, for smartphone use, making it the only Class III medical device for this purpose. The system has assessed over 230,000 patients in 24 NHS hospitals, identifying more than 20,000 cancers, and supports autonomous discharge of up to 40% of urgent referrals. It is planned for availability from June 2026.PR NewswireThe AI from Skin Analytics that caught 20,000 cancers in the UK is now certified for use on a standard smartphoneSkin Analytics unveiled DERM Zero at HLTH Europe in Amsterdam on June 15–16, 2026, becoming the first Class III CE-marked medical device technology approved to autonomously assess skin cancer from a standard smartphone. The AI builds on six years of clinical deployment across 24 NHS hospitals where it has assessed over 230,000 patients, detected more than 20,000 cancers, and been independently proven to perform at least as well as face-to-face dermatologist assessment. Skin Analytics is now working with European partners to make DERM Zero available from June 2026, enabling clinical-grade skin cancer checks in primary care, pharmacies, or community settings without requiring hospital appointments or specialist equipment.TechRoundMeet The Startups Crowdfunding w/c 27.05.2026Five startups are crowdfunding this week, including Skin Analytics, TiPJAR, KLEKT, Sprive, and The Malachite Group. KLEKT and The Malachite Group are 95% funded with limited time remaining, while others are in early access or equity raises.The Manila TimesAffidea partners with Skin Analytics to improve access to skin cancer assessment across Europe using AI technologyAffidea partnered with Skin Analytics to deploy DERM, an AI medical device for skin lesion analysis, starting in Romania and Lithuania with Greece following in September. The partnership aims to improve access to skin cancer care across Europe, with plans to roll out the solution in additional markets.GlobeNewswireAffidea partners with Skin Analytics to improve access to skin cancer assessment across Europe using AI technologyAffidea, a pan-European healthcare provider operating over 410 centers across 15 countries, has partnered with Skin Analytics to implement the latter's DERM AI medical device for automated skin lesion analysis. The initial rollout began in Romania, Lithuania, and Greece, with plans to expand the AI-powered skin cancer screening solution across additional European markets. The partnership aims to improve early detection of skin cancer and address rising demand for dermatology services, building on Skin Analytics' track record of over 180,000 NHS patient cases and 15,500+ cancers identified in the UK.